3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neuroblastoma
9
Melanoma
4
Ganglioneuroblastoma
4
Triple Negative Breast Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Transplant-Related Hematologic Malignancy
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
18
Nivolumab
13
avelumab
10
Ipilimumab
7
Specimen Handling
6
cemiplimab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Radiotherapy
3
Cyclophosphamide
3
prednylidene
2
poly ICLC
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
deltacortene
2
aldesleukin
2
Radiosurgery
2
Prednisone
2
Interleukin-2
2
Immunoglobulin G
2
Docetaxel
2
CTLA-4 Antigen
2
Bevacizumab
2
tocilizumab
1
talimogene laherparepvec
1
sargramostim
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
sargramostim
×
1 year
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled